Date: 2015-07-21
Type of information: Nomination
Compound:
Company: Intercept Pharmaceuticals (USA - NY)
Therapeutic area: Liver diseases - Hepatic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 21, 2015, Intercept Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH), announced the appointment of Richard Kim as Senior Vice President, Commercial Head of U.S. Mr. Kim most recently served as General Manager, Hepatitis C, Worldwide Commercialization at Bristol-Myers Squibb, where he led the worldwide strategy and commercialization for daclatavir and asunaprevir. During his tenure at Bristol-Myers Squibb, Mr. Kim held multiple positions of increasing responsibility over more than ten years, co-leading a national Cardiovascular and Metabolics sales force and managing both U.S. and global commercial activities for a portfolio of oncology therapies. Prior to joining Bristol-Myers Squibb, Mr. Kim worked at Schering-Plough (now a part of Merck & Co.) holding various positions in Canada, the U.S., and Australia.
Financial terms:
Latest news:
